Vitamin D3 Metabolism in Human Glioblastoma Multiforme: Functionality of CYP27B1 Splice Variants, Metabolism of Calcidiol, and Effect of Calcitriol

Purpose: A better understanding of the vitamin D3 metabolism is required to evaluate its potential therapeutic value for cancers. Here, we set out to contribute to the understanding of vitamin D3 metabolism in glioblastoma multiforme. Experimental Design: We did nested touchdown reverse transcription-PCR (RT-PCR) to identify CYP27B1 splice variants and real-time RT-PCR to quantify the expression of CYP27B1. A cell line was treated with calcitriol to determine the effect on the expression of CYP27B1, 1α,25-dihydroxyvitamin D3-24-hydroxylase (CYP24), and vitamin D3 receptor (VDR). We generated three antibodies for the specific detection of CYP27B1 and splice variants. High-performance TLC was done to determine the endogenous CYP27B1 activity and the functionality of CYP27B1 splice variants. Using WST-1 assay, we determined the effect of vitamin D3 metabolites on proliferation. Results: We report a total of 16 splice variants of CYP27B1 in glioblastoma multiforme and a different expression of CYP27B1 and variants between glioblastoma multiforme and normal tissues. We found preliminary evidence for enzymatic activity of endogenous CYP27B1 in glioblastoma multiforme cell cultures but not for the functionality of the splice variants. By adding calcitriol, we found a proliferative effect for some cell lines depending on the dose of calcitriol. The administration of calcitriol led to an elevated expression of CYP27B1 and CYP24 but left the expression of the VDR unaltered. Conclusions: Our findings show that glioblastoma multiforme cell lines metabolize calcidiol. In addition, we show various effects mediated by calcitriol. We found a special vitamin D3 metabolism and mode of action in glioblastoma multiforme that has to be taken into account in future vitamin D3–related therapies.

[1]  G. Butti,et al.  Effects of vitamin D and retinoic acid on human glioblastoma cell lines , 2005, Acta Neurochirurgica.

[2]  E. Meese,et al.  Analysis of the vitamin D system in basal cell carcinomas (BCCs) , 2004, Laboratory Investigation.

[3]  U. Fischer,et al.  Towards a complete picture of splice variants of the gene for 25-hydroxyvitamin D31α-hydroxylase in brain and skin cancer , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[4]  J. Reichrath,et al.  Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  K. Inouye,et al.  C-3 Epimerization of Vitamin D3 Metabolites and Further Metabolism of C-3 Epimers , 2004, Journal of Biological Chemistry.

[6]  P. Tuohimaa,et al.  25‐Hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  H. Taubert,et al.  MDM2 and its splice variant messenger RNAs: expression in tumors and down-regulation using antisense oligonucleotides. , 2004, Molecular cancer research : MCR.

[8]  J. Honnorat,et al.  Redifferentiation Therapy in Brain Tumors: Long-lasting Complete Regression of Glioblastomas and an Anaplastic Astrocytoma Under Long Term 1-alpha-hydroxycholecalciferol , 2004, Journal of Neuro-Oncology.

[9]  Aristides G. Eliopoulos,et al.  Differential Regulation of Vitamin D Receptor and Its Ligand in Human Monocyte-Derived Dendritic Cells1 , 2003, The Journal of Immunology.

[10]  H. DeLuca,et al.  Regulation of 25‐hydroxyvitamin D3‐24‐hydroxylase mRNA by 1,25‐dihydroxyvitamin D3 and parathyroid hormone , 2003, Journal of cellular biochemistry.

[11]  C. Noe,et al.  Induction of apoptosis by vitamin D metabolites and analogs in a glioma cell line. , 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[12]  M. Soloway,et al.  Regulation of Hyaluronidase Activity by Alternative mRNA Splicing* , 2002, The Journal of Biological Chemistry.

[13]  P. Hutchinson,et al.  Vitamin D and systemic cancer: is this relevant to malignant melanoma? , 2002, The British journal of dermatology.

[14]  D. Tong,et al.  Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  S. Bell,et al.  Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. , 2002, Cancer research.

[16]  François Berger,et al.  New clues about vitamin D functions in the nervous system , 2002, Trends in Endocrinology & Metabolism.

[17]  U. Fischer,et al.  Expression, cellular distribution and protein binding of the glioma amplified sequence (GAS41), a highly conserved putative transcription factor , 2001, Oncogene.

[18]  W Feiden,et al.  PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme , 2001, Oncogene.

[19]  C. Carlberg,et al.  Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. , 2001, Frontiers in bioscience : a journal and virtual library.

[20]  U. Fischer,et al.  Amplification and expression of splice variants of the gene encoding the P450 cytochrome 25-hydroxyvitamin D(3) 1,alpha-hydroxylase (CYP 27B1) in human malignant glioma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  J. McNeal,et al.  Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. , 2001, Cancer research.

[22]  I. Schuster,et al.  Selective inhibitors of CYP24: mechanistic tools to explore vitamin D metabolism in human keratinocytes , 2001, Steroids.

[23]  A. Howie,et al.  Extrarenal Expression of 25-Hydroxyvitamin D3-1α-Hydroxylase1 , 2001 .

[24]  M. Seldin,et al.  25‐Hydroxyvitamin D 1α‐Hydroxylase: Structure of the Mouse Gene, Chromosomal Assignment, and Developmental Expression , 2001 .

[25]  A. Howie,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Extrarenal Expression of 25-Hydroxyvitamin , 2022 .

[26]  J. Zou,et al.  Correlation of a unique 220-kDa protein with vitamin D sensitivity in glioma cells. , 2000, Biochemical pharmacology.

[27]  T. Saruta,et al.  Identification of 25-hydroxyvitamin D3 1alpha-hydroxylase gene expression in macrophages. , 2000, Kidney international.

[28]  J. Moringlane,et al.  Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells. , 1999, Journal of neuropathology and experimental neurology.

[29]  H. Ramshaw,et al.  Expression and Activity of Vitamin D-Metabolizing Cytochrome P450s (CYP1α and CYP24) in Human Nonsmall Cell Lung Carcinomas. , 1999, Endocrinology.

[30]  M. Hewison,et al.  Constitutive Expression of 25-Hydroxyvitamin D3-1α-Hydroxylase in a Transformed Human Proximal Tubule Cell Line: Evidence for Direct Regulation of Vitamin D Metabolism by Calcium. , 1999, Endocrinology.

[31]  M. Hentze,et al.  A Perfect Message RNA Surveillance and Nonsense-Mediated Decay , 1999, Cell.

[32]  M. Meurer,et al.  Human keratinocyte line HaCaT metabolizes 1α-hydroxyvitamin D3 and vitamin D3 to 1α,25-dihydroxyvitamin D3 (calcitriol) , 1998 .

[33]  H. DeLuca,et al.  Current understanding of the molecular actions of vitamin D. , 1998, Physiological reviews.

[34]  H. Cross,et al.  Differentiation-Related Pathways of 1α,25-Dihydroxycholecalciferol Metabolism in Human Colon Adenocarcinoma-Derived Caco-2 Cells: Production of 1α,25-Dihydroxy-3epi-cholecalciferol , 1998 .

[35]  T. Chen,et al.  Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[36]  G. Butti,et al.  Vitamin D Metabolites Activate the Sphingomyelin Pathway and Induce Death of Glioblastoma Cells , 1998, Acta Neurochirurgica.

[37]  D. Feldman,et al.  Vitamin D: anticancer and differentiation. , 1997 .

[38]  P. Brachet,et al.  1,25‐Dihydroxyvitamin D3 induces programmed cell death in a rat glioma cell line , 1996, Journal of neuroscience research.

[39]  R. Wernyj,et al.  Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. , 1996, The Biochemical journal.

[40]  H. Pols,et al.  Differential effects of 1,25-dihydroxyvitamin D3-analogs on osteoblast-like cells and onin vitro bone resorption , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[41]  R. Bouillon,et al.  Structure-function relationships in the vitamin D endocrine system. , 1995, Endocrine reviews.

[42]  J. Doehmer,et al.  Cloning and stable expression of the human mitochondrial cytochrome P45011B1 cDNA in V79 Chinese hamster cells and their application for testing of potential inhibitors. , 1995, Pharmacogenetics.

[43]  B. Lake,et al.  Expression and alternative splicing of the cytochrome P-450 CYP2A7. , 1995, The Biochemical journal.

[44]  D. Baran Nongenomic actions of the steroid hormone 1α25‐dihydroxyvitamin D3 , 1994 .

[45]  P. Brachet,et al.  Synthesis of 1,25‐dihydroxyvitamin D3 by rat brain macrophages in vitro , 1994, Journal of neuroscience research.

[46]  A. Benabid,et al.  Induction of glioma cell death by 1,25 (OH)2 vitamin D3: Towards an endocrine therapy of brain tumors? , 1994, Journal of neuroscience research.

[47]  A. Norman,et al.  Selective biological response by target organs (intestine, kidney, and bone) to 1,25-dihydroxyvitamin D3 and two analogues. , 1993, Cancer research.

[48]  N. Bell Vitamin D-endocrine system. , 1985, The Journal of clinical investigation.

[49]  I. Nemere,et al.  Early actions of parathyroid hormone and 1,25-dihydroxycholecalciferol on isolated epithelial cells from rat intestine: II. Analyses of additivity, contribution of calcium, and modulatory influence of indomethacin. , 1981, Endocrinology.